03:30:51 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-10 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-17 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-24 Bokslutskommuniké 2022
2022-11-29 Extra Bolagsstämma 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-18 Ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-31 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-01 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget är inriktade mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande läkemedelskandidater. Huvudkontoret ligger i Huddinge.
2022-10-11 08:30:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s presentation at the scientific conference ISMND 2022 is now available in its entirety on the company website. The abstract demonstrates new preclinical data with the company’s leading drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease.

The abstract, titled The Trk-PAM ACD856 improves mitochondrial function and increase BDNF levels in primary cortical neurons, was presented by Pontus Forsell, Head of Research and Discovery på AlzeCure, and includes new preclinical data on ACD856, the lead drug candidate in the NeuroRestore project.

Data from the study show that ACD856 has a potential neuroprotective effect in a cellular model of nerve injury. These protective properties are believed to be mediated by an improved mitochondrial function and a protective effect on the structure of the cell, which has been demonstrated in the presented studies. Furthermore, ACD856 also increases the release of Brain Derived Neurotrophic Factor, BDNF, from the cells, something that is believed to further enhance these positive effects.

ACD856, which is a positive modulator of both NGF/TrkA and BDNF/TrkB mediated signaling, has demonstrated in preclinical studies to improve cognition and memory and is ready for phase 2 clinical studies, where it is being developed primarily for the treatment of Alzheimer's disease.

”These new data demonstrate potential disease-modifying effects of ACD856, in addition to the positive effects we have seen on memory and learning. The neuroprotective properties we see are important, as dysfunction and loss of neurons correlates strongly with impaired function in Alzheimer's patients,” said Pontus Forsell.
 
”We are very excited about the new results with ACD856, which significantly strengthen the commercial potential of the project. It also opens up possibilities for new indication areas," said Martin Jönsson, CEO of AlzeCure.

The authors of the abstract are Cristina Parrado, Sanja Juric, Märta Dahlström, Pontus Forsell and Johan Sandin, CSO at AlzeCure.

The presentation is available on AlzeCure’s website (https://www.alzecurepharma.se/en/publications).